FDA accelerated approval benefits glioblastoma

被引：21

|

作者：

Cloughesy, Timothy ^{[1
]}

机构：

[1] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA

来源：

LANCET ONCOLOGY | 2010年 / 11卷 / 12期

关键词：

D O I：

10.1016/S1470-2045(10)70269-2

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

收藏

页码：1120 / 1120

页数：1

相关论文

共 50 条

[1] FDA accelerated approval under scrutiny
不详
[J]. JOURNAL OF INVESTIGATIVE MEDICINE, 2005, 53 (06) : 290 - 290
[2] FDA accelerated approval of anticancer agents
Ning, Y. M.
Johnson, J. R.
Farrell, A. T.
Maher, V. E.
Justice, R. L.
Pazdur, R.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[3] FDA granted accelerated approval to ibrutinib(IMBRUVICA)
[J]. Journal of Chinese Pharmaceutical Sciences, 2014, (04) : 273 - 273
[4] The FDA Accelerated Drug Approval Program Explained
不详
[J]. US PHARMACIST, 2023, 48 (10) : 56 - 57
[5] Surrogate endpoints and FDA's accelerated approval process
Fleming, TR
[J]. HEALTH AFFAIRS, 2005, 24 (01) : 67 - 78
[6] Modernising the US FDA's Accelerated Approval pathway
Benjamin, David J.
Lythgoe, Mark P.
[J]. LANCET ONCOLOGY, 2023, 24 (03): : 203 - 205
[7] Accelerated Approval - Taking the FDA's Concerns Seriously
Sachs, Rachel E.
Donohue, Julie M.
Dusetzina, Stacie B.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (03): : 199 - 203
[8] CLINICAL BENEFITS OF THE ACCELERATED APPROVAL PROGRAM IN ONCOLOGY
Ortendahl, J.
Epstein, J.
[J]. VALUE IN HEALTH, 2024, 27 (06) : S217 - S218
[9] HHS Inspector General to Review FDA Accelerated Approval Pathway
不详
[J]. JOURNAL OF NUCLEAR MEDICINE, 2021, 62 (10): : 18 - 18
[10] FDA and Congress Re-Examine Accelerated Approval Program
Wechsler, Jill
[J]. BIOPHARM INTERNATIONAL, 2022, 35 (04) : 9 - 9

← 1 2 3 4 5 →